Business
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectivelyBridgeBio reported three positive Phase 3 trial readouts in just over three months, a demonstration of its unique model for sustainable drug development as described in a recent peer-reviewed manuscriptAttruby continues to demonstrate clinical differentiation as a first-choice therapy in ATTR-CM with the
About this update from Bridgebio Pharma, Inc.
[{"type":"image","alt":"BridgeBio Pharma, Inc.","displaySize":"","headline":null,"caption":"BridgeBio Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/67d229c5dfa70aa930ee69ce2872e9be"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z3roQwquAczfyVwH352A4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/67d229c5dfa70aa930ee69ce2872e9be","width":300,"height":47}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectively","length":194,"tagName":"p"}]},{"val":[{"type":"text","content":"BridgeBio reported three positive Phase 3 trial readouts in just over three months, a demonstration of its unique model for sustainable drug development as described in a recent peer-reviewed manuscript","length":202,"tagName":"p"}]},{"val":[{"type":"text","content":"Attruby continues to demonstrate clinical differentiation as a first-choice therapy in ATTR-CM with the greatest TTR stabilization on the market (≥90%) and the most rapid benefit on clinical outcomes observed within 1 month, with 7,804 unique patient prescriptions written by 1,856 unique prescribers as of February 20, 2026","length":324,"tagName":"p"}]},{"val":[{"type":"text","content":"PROPEL 3 for oral infigratinib successfully met its primary endpoint (p<0.0001). The change from baseline in AHV was superior to placebo at Week 52, with a mean treatment difference against placebo of +2.10 cm/year; topline results showed the first statistically significant improvements in body proportionality in achondroplasia","length":332,"tagName":"p"}]},{"val":[{"type":"text","content":"Positive interim Phase 3 FORTIFY results for BBP-418 in LGMD2I/R9 demonstrated a statistically significant and clinically meaningful 2.6-point NSAD improvement versus placebo at 12 months; FDA recommended pursuing traditional approval, supporting a planned 1H 2026 NDA submission and a U.S. launch anticipated in late 2026/early 2027","length":333,"tagName":"p"}]},{"val":[{"type":"text","content":"On track for a 1H 2026 NDA submission following positive Phase 3 CALIBRATE results for en...